1. Home
  2. MXL vs VTVT Comparison

MXL vs VTVT Comparison

Compare MXL & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxLinear Inc.

MXL

MaxLinear Inc.

HOLD

Current Price

$17.41

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$34.00

Market Cap

127.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MXL
VTVT
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
127.0M
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
MXL
VTVT
Price
$17.41
$34.00
Analyst Decision
Buy
Strong Buy
Analyst Count
7
3
Target Price
$20.25
$37.00
AVG Volume (30 Days)
1.4M
12.4K
Earning Date
01-28-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$423,372,000.00
$17,000.00
Revenue This Year
$30.54
N/A
Revenue Next Year
$18.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.53
N/A
52 Week Low
$8.35
$13.15
52 Week High
$25.73
$35.95

Technical Indicators

Market Signals
Indicator
MXL
VTVT
Relative Strength Index (RSI) 55.78 70.06
Support Level $15.18 $22.92
Resistance Level $19.64 $35.95
Average True Range (ATR) 0.83 2.23
MACD 0.26 0.59
Stochastic Oscillator 60.37 89.87

Price Performance

Historical Comparison
MXL
VTVT

About MXL MaxLinear Inc.

MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.

Share on Social Networks: